Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats

  • Yoon, Namsik (Department of Cardiology, Chonnam National University Hospital) ;
  • Kim, Kye Hun (Department of Cardiology, Chonnam National University Hospital) ;
  • Park, Keun Ho (Department of Cardiology, Chonnam National University Hospital) ;
  • Sim, Doo Sun (Department of Cardiology, Chonnam National University Hospital) ;
  • Youn, Hyun Ju (Department of Cardiology, Chonnam National University Hospital) ;
  • Hong, Young Joon (Department of Cardiology, Chonnam National University Hospital) ;
  • Park, Hyung Wook (Department of Cardiology, Chonnam National University Hospital) ;
  • Kim, Ju Han (Department of Cardiology, Chonnam National University Hospital) ;
  • Ahn, Youngkeun (Department of Cardiology, Chonnam National University Hospital) ;
  • Jeong, Myung Ho (Department of Cardiology, Chonnam National University Hospital) ;
  • Cho, Jeong Gwan (Department of Cardiology, Chonnam National University Hospital) ;
  • Park, Jong Chun (Department of Cardiology, Chonnam National University Hospital)
  • Published : 2013.10.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: It is widely known that angiotensin-II receptor blockers (ARBs) have reverse remodeling effects in atrium. Although atrial fibrillation is frequent in ischemic heart failure clinically, experiments to demonstrate ARB's effects on atrial remodeling in a heart failure model are rare. Materials and Methods: A heart failure model and a sham-operated group were formed in 25 Sprague-Dawley male rats of roughly 260 g in weight. Ischemic heart failure models were obtained via ligation of the left anterior descending coronary artery. In the ARB group, 30 mg/kg of losartan was administrated over a day for 4 weeks. Echocardiography was performed to measure left ventricle ejection fraction and left atrial diameter (LAD) at the baseline and 4 weeks after the operation. 4 weeks later, histologic and immunohistochemical evaluation were performed. Results: Groups were divided into the sham group, heart failure group, and heart failure-ARB group. We maintained 5 rats in each group for 4 weeks after operation. The decrease of left ventricular ejection fraction in the heart failure-ARB group was less than that in the heart failure group (p=0.023). The increase of LAD in the heart failure-ARB group was less than that in the heart failure group (p=0.025). Masson's trichrome stain revealed less fibrosis in the heart failure-ARB group. Immunohistochemical stain and western blot for connexin 43 showed less expression in the heart failure-ARB group. Conclusion: In the ischemic heart failure model of rats, structurally and histologically, the ARB, losartan, has atrial reverse-remodeling effects. However, electrically, its role as an electrical stabilizer should be studied further.

Keywords

References

  1. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204. https://doi.org/10.1016/S0735-1097(03)00464-9
  2. Wollert KC, Drexler H. The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. Am J Cardiol 1997;80:158A-61A. https://doi.org/10.1016/S0002-9149(97)00473-6
  3. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77. https://doi.org/10.1016/S0735-1097(00)00611-2
  4. Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the reninangiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol 2008;66:345-51. https://doi.org/10.1111/j.1365-2125.2008.03234.x
  5. Boixel C, Fontaine V, Rucker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003;42:336-44. https://doi.org/10.1016/S0735-1097(03)00578-3
  6. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63. https://doi.org/10.1161/01.CIR.96.9.3157
  7. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95. https://doi.org/10.1161/01.CIR.100.1.87
  8. Dhein S. Role of connexins in atrial fibrillation. Adv Cardiol 2006;42:161-74.
  9. Gollob MH. Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Curr Opin Cardiol 2006;21:155-8. https://doi.org/10.1097/01.hco.0000221574.95383.6f
  10. Daniels MC, Keller RS, de Tombe PP. Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H2150-8. https://doi.org/10.1152/ajpheart.2001.281.5.H2150
  11. Johns TN, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surg 1954;140:675-82. https://doi.org/10.1097/00000658-195411000-00006
  12. Jalife J. Experimental and clinical AF mechanisms: bridging the divide. J Interv Card Electrophysiol 2003;9:85-92. https://doi.org/10.1023/A:1026251517004
  13. Takeuchi S, Akita T, Takagishi Y, et al. Disorganization of gap junction distribution in dilated atria of patients with chronic atrial fibrillation. Circ J 2006;70:575-82. https://doi.org/10.1253/circj.70.575
  14. Miyauchi Y, Zhou S, Okuyama Y, et al. Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation. Circulation 2003;108:360-6. https://doi.org/10.1161/01.CIR.0000080327.32573.7C
  15. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992;19:1136-44. https://doi.org/10.1016/0735-1097(92)90314-D
  16. Thomas SA, Schuessler RB, Berul CI, et al. Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction: evidence for chamber-specific molecular determinants of conduction. Circulation 1998;97:686-91. https://doi.org/10.1161/01.CIR.97.7.686
  17. Kato T, Iwasaki YK, Nattel S. Connexins and atrial fibrillation: filling in the gaps. Circulation 2012;125:203-6. https://doi.org/10.1161/CIRCULATIONAHA.111.075432
  18. Hoyano M, Ito M, Kimura S, et al. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc Pathol 2010;19:e149-57. https://doi.org/10.1016/j.carpath.2009.07.002
  19. Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012;33:2098-108. https://doi.org/10.1093/eurheartj/ehr266
  20. Rucker-Martin C, Milliez P, Tan S, et al. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res 2006;72:69-79. https://doi.org/10.1016/j.cardiores.2006.06.016
  21. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-7. https://doi.org/10.1161/01.CIR.101.22.2612
  22. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420. https://doi.org/10.1093/europace/euq350
  23. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413. https://doi.org/10.1093/europace/eus305

Cited by

  1. A New Chimeric Natriuretic Peptide, C N AA C , for the Treatment of Left Ventricular Dysfunction after Myocardial Infarction vol.7, pp.None, 2013, https://doi.org/10.1038/s41598-017-10748-6
  2. Renin-Angiotensin System Inhibitors for the Prevention of Atrial Fibrillation Recurrence After Ablation ― A Meta-Analysis ― vol.84, pp.10, 2020, https://doi.org/10.1253/circj.cj-20-0402